Truist analyst Jailendra Singh downgraded Phreesia (PHR) to Hold from Buy with a price target of $11, down from $24. The company’s Q4 earnings release came with a “meaningful reduction” to its fiscal 2027 revenue outlook, the analyst tells investors in a research note. Trust says the Phreesia narrative has shifted from “show me” to “no growth visibility.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHR:
- Phreesia: Solid Operating Leverage but Regulatory Headwinds and Slowing Life Sciences Growth Warrant Hold Rating
- Balanced View on Phreesia: Solid Profitability Gains Offset by Weaker Growth Visibility and Elevated Execution Risk Supporting a Hold Rating
- Balanced View on Phreesia: Solid Profitability and Valuation Support Offset by Growth Uncertainty and Estimate Revisions
- Closing Bell Movers: Phreesia down over 20% after guidance cut
- Phreesia cuts FY27 revenue view to $510M-$520M from $545M-$559M